1. The median overall survival for patients receiving177Lu-Dotatate and intramuscular, long-acting octreotide was 47.0 months and 36.3 months respectively 2....
1. This is the first human clinical trial of evorpacept, a CD47 inhibitor, and the results suggest an acceptable safety...
1. The median disease-free survival for gefitinib group and cisplatin/vinorelbine group was 35.9 and 25.1 months, respectively. 2. Patients receiving...
1. Intracranial response rate of 55% was reported in patients receiving cabozantinib with progressing brain metastases with no concomitant brain-directed...
1. For the detection of pelvic nodal metastases in men with intermediate-to high-risk prostate cancer, using the 68Ga-PSMA-11 PET scan,...
![Shorter moxifloxacin-containing regimens ineffective for treating TB [REMoxTB trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/TB-original-e1591582219420-350x250.jpg)
1. Compared to the gemcitabine with placebo group, the gemcitabine with ramucirumab group had longer overall survival as a potential...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
